Search clinical trials for: Non-squamous NSCLC

Total 3654 results

Guangdong Association of Clinical Trials

Unknown

Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC

Advanced Non-squamous NSCLC

China
Lingyu Luo

Unknown

Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin

Non-squamous Non-small Cell Lung Cancer
AIO-Studien-gGmbH
AstraZeneca

Terminated

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB (NeoIntercal)

NSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR Mutation

Germany
Amgen

Terminated

A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

Advanced Non-squamous NSCLC
Jian Fang
Peking University First Hospital; Peking University Third Hospital; The Second...

Unknown

Apatinib in Advanced Non-squamous，NSCLC

Non-squamous Non-Small Cell Lung Cancer

China
Postgraduate Institute of Medical Education and...

Completed

Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy (PEMVITASTART)

Anemia | Thrombocytopenia | Neutropenia | Lung Adenocarcinoma | Nonsquamous Nonsmall Cell Neoplasm of Lung

India
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR) (ANSWER)

Carcinoma, Non-Small-Cell Lung

China
Hoffmann-La Roche

Completed

An Observational Study on Patients With Non-Squamous NSCLC Who Reached A Long PFS After Avastin (Bevacizumab)-Based First-Line Therapy

Non-Squamous Non-Small Cell Lung Cancer

Spain
PD Dr. med. Wolfgang Schuette
Eli Lilly and Company; Roche Pharma AG

Completed

Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer (65plus)

Non-squamous Non-small Cell Lung Cancer

Germany
Providence Health & Services
Bristol-Myers Squibb; Genentech, Inc.

Terminated

Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Non-squamous Non-small Cell Lung Cancer

United States
Spanish Lung Cancer Group

Terminated

Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC (Phalcis)

Carcinoma, Non Small Cell Lung

Spain
University of Athens

Completed

Bevacizumab in Combination With Chemotherapy in Patients With Advanced or Recurrent Non-squamous NSCLC

Non-small Cell Lung Cancer | Unresectable Malignant Neoplasm

Greece
Taipei Veterans General Hospital, Taiwan
National Taiwan University Hospital; China Medical University Hospital; Tri-Service... and other collaborators

Unknown

Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy

NSCLC

Taiwan
WiSP Wissenschaftlicher Service Pharma GmbH
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Suspended

Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Germany
Barbara Ann Karmanos Cancer Institute

Withdrawn

Integration of Neutron Therapy in the Treatment Plan for Stage III Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer
Eli Lilly and Company

Completed

Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.

Hungary, Germany, Austria, Spain, Sweden
Shanghai Chest Hospital

Not yet recruiting

Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLC

Non-Small-Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (ACCLAIM)

NSCLC | PD-1

China
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First-line Treatment

NSCLC
Tang-Du Hospital

Not yet recruiting

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

Non-Small Cell Lung Cancer | Anti Angiogenesis

China
Bristol-Myers Squibb

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

Non-small Cell Lung Cancer (NSCLC) | High-grade Serous Ovarian Carcinoma (HGSOC) | Uterine Serous Carcinoma (USC)

United States, Canada
Shanghai Juncell Therapeutics

Not yet recruiting

A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of NSCLC (MIZAR-005)

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic
GlaxoSmithKline
iTeos Therapeutics

Recruiting

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Lung Cancer, Non-Small Cell

Argentina, Belgium, Brazil, Canada, Finland, Germany, Italy, Japan, Mexico, Panama, Spain, Taiwan, Turkey, Poland, Netherlands, Korea, Republic of, France, Greece, Bulgaria, Croatia, Czechia, Estonia, Hong Kong, Hungary, India, Philippines, Portuga... and more
Beijing Chest Hospital, Capital Medical University

Not yet recruiting

Adebrelimab Plus Chemo and Recaticimab Perioperative Treatment for Resectable NSCLC

Non Small Cell Lung Cancer

China
MSD Italia S.r.l.

Not yet recruiting

A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced (Key-Early)

NSCLC | Non-small Cell Lung Cancer | NSCLC, Stage III | NSCLC, Stage I
Regeneron Pharmaceuticals

Not yet recruiting

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer
Henan Cancer Hospital

Not yet recruiting

Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC

NSCLC

China
Genelux Corporation
Newsoara Biopharma Co., Ltd.

Not yet recruiting

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25) ((VIRO-25))

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Advanced Non-squamous Non-small-cell Lung Cancer | Non-small Cell Lung Cancer Stage IV | Metastatic Squamous Non-Small Cell Lung Carcinoma | Non-small Cell Lung Cancer Recurrent | Metastatic Non-squamous Non Small Cell Lung Cancer and other conditions
Eli Lilly and Company
Loxo Oncology, Inc.

Not yet recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01)

Cervical Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Renal Pelvis Cancer | Urinary Bladder Neoplasm | Recurrent...

United States
European Organisation for Research and Treatment...

Not yet recruiting

OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT) (SPRINT)

Breast Cancer | Colorectal Cancer | NSCLC | Prostate Cancer | Oligometastatic Disease
Guangzhou University of Traditional Chinese Medicine
Jiangsu Province Hospital of Traditional Chinese Medicine; The First Affiliated...

Not yet recruiting

Acupuncture for Enhancing Immunotherapy in Advanced NSCLC：a Pilot Study

Non-small Cell Lung Cancer | Non-Small-Cell Lung Carcinoma

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

Locally Advanced or Metastatic NSCLC
Shanghai Chest Hospital
Novartis; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; BeiGene

Not yet recruiting

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

KRAS Mutation-Related Tumors | Advanced Lung Cancer | Refractory Tumor

China
Amsterdam UMC, location VUmc
Foundation for the National Institutes of Health

Not yet recruiting

Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer (iRelate)

NSCLC

Netherlands
Henan Cancer Hospital

Not yet recruiting

Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer NSCLC
University Hospital, Basel, Switzerland

Not yet recruiting

TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients (BaseTIL-02)

Non-Small Cell Lung Cancer

Switzerland
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer
Bayer

Not yet recruiting

A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2) (SOHO-02)

Advanced Non-small Cell Lung Cancer | HER2 Mutation

United States, China, Korea, Republic of, Belgium, Hong Kong, Japan, Taiwan, Denmark, Germany, Israel, Poland, Italy, United Kingdom, Bulgaria, Czechia, Portugal, Switzerland, Greece, Turkey, Romania, Sweden, France, Singapore, Mexico, ... and more
Bristol-Myers Squibb

Not yet recruiting

Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

Non-small Cell Lung Cancer (NSCLC)

United Kingdom
Pfizer

Not yet recruiting

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Carcinoma, Pancreatic Ductal

Puerto Rico
Fudan University

Not yet recruiting

The Efficacy and Safety of Cadonilimab (AK104) as Induction and Consolidation Therapy for Locally Advanced/Unresectable NSCLC Patients Receiving Concurrent Chemoradiotherapy

NSCLC | Locally Advanced Lung Carcinoma

China
University Hospital, Lille
Exeliom Biosciences

Not yet recruiting

EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy. (EXLIBRIS)

Non-Small Cell Lung Cancer
First Affiliated Hospital of Zhejiang University

Recruiting

Efficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment (MSJZT-NSCLC)

Non Small Cell Lung Cancer | Perioperative Complication

China
Shanghai Chest Hospital

Recruiting

A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital
Hunan Cancer Hospital

Recruiting

Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases (EPIC)

Non-Small Cell Lung Cancer

China
Karl Landsteiner Institute for Lung Research and...
Klinik Pirawarth; Therme Wien Med

Not yet recruiting

Outpatient Pulmonary Rehabilitation in Non-small-cell Lung Cancer Receiving Immunotherapy (OPAL)

NSCLC Stage IV
Henan Cancer Hospital

Recruiting

An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
Shanghai Chest Hospital

Not yet recruiting

Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH) (neoR-TORCH)

Stage II-III Non-small Cell Lung Cancer
Sir Run Run Shaw Hospital

Not yet recruiting

A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC

Non-Small-Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC

Advanced Non-small Cell Lung Cancer

Search clinical trials for: Non-squamous NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations